| Primary |
| Heparin-induced Thrombocytopenia |
32.6% |
| Sedation |
7.3% |
| Anticoagulant Therapy |
6.7% |
| Cerebral Infarction |
6.1% |
| Prophylaxis |
5.0% |
| Embolic Stroke |
4.2% |
| Pneumonia |
3.7% |
| Analgesic Therapy |
3.4% |
| Medical Diet |
3.4% |
| Thrombotic Cerebral Infarction |
3.4% |
| Infection |
2.7% |
| Prophylaxis Against Gastrointestinal Ulcer |
2.7% |
| Anaemia |
2.6% |
| Hypertension |
2.6% |
| Hypovolaemia |
2.5% |
| Diabetes Mellitus |
2.4% |
| Endocarditis |
2.3% |
| Peritonitis |
2.2% |
| Pulmonary Embolism |
2.1% |
| Supplementation Therapy |
2.1% |
|
| International Normalised Ratio Increased |
24.8% |
| Coagulation Time Prolonged |
15.6% |
| Haemorrhage |
6.7% |
| Activated Partial Thromboplastin Time Prolonged |
6.3% |
| Sepsis |
4.8% |
| Hepatic Function Abnormal |
4.4% |
| Gastrointestinal Haemorrhage |
4.1% |
| Death |
3.3% |
| Platelet Count Decreased |
3.3% |
| Drug Ineffective |
3.0% |
| Thrombosis |
3.0% |
| Hepatic Enzyme Increased |
2.6% |
| Prothrombin Time Prolonged |
2.6% |
| Activated Partial Thromboplastin Time Abnormal |
2.2% |
| Haemorrhagic Cerebral Infarction |
2.2% |
| Liver Function Test Abnormal |
2.2% |
| Overdose |
2.2% |
| Pulmonary Embolism |
2.2% |
| Rectal Haemorrhage |
2.2% |
| Septic Shock |
2.2% |
|
| Secondary |
| Product Used For Unknown Indication |
21.7% |
| Drug Use For Unknown Indication |
12.6% |
| Heparin-induced Thrombocytopenia |
9.7% |
| Pulmonary Embolism |
6.4% |
| Deep Vein Thrombosis |
6.3% |
| Thrombosis Prophylaxis |
6.3% |
| Cerebral Infarction |
6.1% |
| Pneumonia |
4.7% |
| Prophylaxis |
4.4% |
| Anticoagulant Therapy |
3.6% |
| Endocarditis |
3.6% |
| Vena Cava Thrombosis |
3.0% |
| Sedation |
2.3% |
| Renal Vein Thrombosis |
2.0% |
| Nutritional Support |
1.8% |
| Diabetes Mellitus |
1.4% |
| Hypertension |
1.1% |
| Infection |
1.1% |
| Embolic Stroke |
1.0% |
| Hyperlipidaemia |
1.0% |
|
| Pulmonary Alveolar Haemorrhage |
12.3% |
| Activated Partial Thromboplastin Time Prolonged |
10.6% |
| Hepatic Function Abnormal |
9.8% |
| Prothrombin Time Prolonged |
8.9% |
| Duodenal Ulcer |
7.7% |
| Activated Partial Thromboplastin Time Abnormal |
5.5% |
| Incorrect Dose Administered |
5.1% |
| Vena Cava Thrombosis |
4.7% |
| Hypertension |
4.3% |
| Coagulation Time Prolonged |
3.8% |
| Gastrointestinal Haemorrhage |
3.8% |
| International Normalised Ratio Increased |
3.4% |
| Melaena |
3.4% |
| Vomiting |
3.4% |
| Sepsis |
3.0% |
| Subdural Haematoma |
2.6% |
| Pulmonary Embolism |
2.1% |
| Thrombosis |
2.1% |
| Gangrene |
1.7% |
| Haemorrhage |
1.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
42.4% |
| Drug Use For Unknown Indication |
34.9% |
| Cerebral Infarction |
3.3% |
| Hypertension |
2.5% |
| Pain |
2.3% |
| Renal Cell Carcinoma |
1.6% |
| Infection |
1.3% |
| Diabetes Mellitus |
1.2% |
| Heparin-induced Thrombocytopenia |
1.2% |
| Anticoagulant Therapy |
1.1% |
| Prophylaxis Against Transplant Rejection |
1.0% |
| Deep Vein Thrombosis |
0.9% |
| Pulmonary Embolism |
0.9% |
| Hyperlipidaemia |
0.9% |
| Pyrexia |
0.9% |
| Respiratory Tract Infection |
0.8% |
| Nausea |
0.7% |
| Prophylaxis |
0.7% |
| Thrombotic Cerebral Infarction |
0.7% |
| Idiopathic Thrombocytopenic Purpura |
0.7% |
|
| Thrombocytopenia |
9.7% |
| Thrombosis |
9.7% |
| Platelet Count Decreased |
7.5% |
| Unresponsive To Stimuli |
6.5% |
| Vomiting |
6.5% |
| Cerebral Infarction |
5.4% |
| Pyrexia |
5.4% |
| Weight Decreased |
5.4% |
| Artery Dissection |
4.3% |
| Hemiparesis |
4.3% |
| Hypoglycaemia |
4.3% |
| Pulmonary Embolism |
4.3% |
| Venous Occlusion |
4.3% |
| Atrial Fibrillation |
3.2% |
| Duodenal Ulcer Haemorrhage |
3.2% |
| Liver Disorder |
3.2% |
| Neutrophil Count Decreased |
3.2% |
| Sepsis |
3.2% |
| Septic Shock |
3.2% |
| Thrombotic Thrombocytopenic Purpura |
3.2% |
|
| Interacting |
| Heparin-induced Thrombocytopenia |
42.9% |
| Urinary Tract Infection |
42.9% |
| Bk Virus Infection |
14.3% |
|
| Drug Interaction |
80.0% |
| Discomfort |
20.0% |
|
